盖诺联合卡培他滨治疗晚期乳腺癌的临床观察

Clinical observation of vinorelbine combined with capecitabine for treating advanced breast carcinoma

目的观察盖诺联合卡培他滨方案治疗晚期乳腺癌的临床疗效和不良反应。方法34例晚期乳腺癌患者应用盖诺25mg/m2,d1、8,静注;卡培他滨2000mg/m2,分两次口服,d114,21d为1周期。化疗过程中注意观察不良反应,连用2周期后按照WHO标准进行疗效及毒副反应评价。结果34例均可以进行疗效评价,CR4例,PR16例,SD12例,PD2例,总有效率58.8%。不良反应主要为骨髓抑制、消化道反应和手足综合征等。结论盖诺联合卡培他滨方案治疗晚期乳腺癌疗效好,毒性低,使用方便、经济,患者耐受性好。

Objective To observe the clinical efficacy of chemotherapy using vinorelbine （NVB） combined with capecitabine in treatment of the patients with advanced breast cancer. Method For 34 patients, chemotherapeutic protocol was vinorelbine （25 mg/m^2, d1, 8 ） and capecitabine （ 2000 mg/m^2, bid, po, d1-14 ）. Every 21 days constituted a cycle and the efficacy was evaluated using WHO standard after 2 cycles of treatment. Results The total response rate of thirty-four patients was 58.8%, with CR 4 cases, PR 16 cases, SD 12 cases and PD 2 cases. Toxic reactions included mild nausea,vomiting and leucopenia. Conclusion The chemotherapy with vinorelbine and capecitabine is an effective and safe method for the patients with advanced breast cancer.